Germany’s Merck KGaA (MKGAY), which had confirmed in February it was in advanced talks to buy SpringWorks Therapeutics (SWTX), is nearing a ...

Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on scPharmaceuticals (SCPH – Research Report) and ...

Sarepta Therapeutics Inc. research and ratings by Barron's. View SRPT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

This afternoon we watched Sarepta Therapeutics rise 5.6% to a price of $58.34 per share. The Mid-Cap Pharmaceutical company is now trading -60.85% below its average target price of $149.0. Analysts ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025.

FAIR Health released the second edition of the Monthly Telehealth Regional Tracker Trending Reports, a free set of infographics that show national and regional trends in telehealth from July to ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of $65.00.

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: ...